- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
There is just a single study in which the pharmacokinetics of alimemazine have been investigated in children (N = 6, median age 6.8 years). The kinetic parameters from this study show wide variations between individuals (t½ = 4.4 to 18.5 hours, median 6.8 hours).
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Premedication |
|---|
|
| Prophylaxis and symptomatic treatment for allergic conditions in which non-sedating antihistamines have proved ineffective or insufficiently effective |
|---|
|
| As an adjuvant with other sedatives |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Paradoxical stimulation of the central nervous system can occur in young children in particular, which can cause sleeplessness, nervousness, confusion, tachycardia, tremors and convulsions.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications in children
Children younger than 2 years because of a possible link with sudden infant death syndrome.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Do not use in children aged under 2 years because of the risk of sedation and respiratory depression; there is a correlation with sudden infant death syndrome. Be careful in children aged less than 6 years because of the greater risk of neuropsychiatric side effects. Be careful in children with sleep apnoea in their previous history, when sudden infant death syndrome is known in the family, when children wake up spontaneously less easily than normal and in very sick or dehydrated children, because such children have an increased incidence of dystonia.
Do not combine with deptropine.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Aminoalkyl ethers | ||
|---|---|---|
| R06AA04 | ||
| R06AA52 | ||
| R06AA02 | ||
| Substituted alkylamines | ||
|---|---|---|
| R06AB03 | ||
| Phenothiazine derivatives | ||
|---|---|---|
| R06AD08 | ||
| R06AD02 | ||
| Piperazine derivatives | ||
|---|---|---|
| R06AE07 | ||
| R06AE03 | ||
| R06AE09 | ||
| R06AE05 | ||
| Other antihistamines for systemic use | ||
|---|---|---|
| R06AX18 | ||
| R06AX29 | ||
| R06AX02 | ||
| R06AX27 | ||
| R06AX26 | ||
| R06AX17 | ||
| R06AX13 | ||
| R06AX25 | ||
| R06AX28 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Kahn A, et al, Phenothiazines and Sudden Infant Death Syndrome., Pediatrics, 1982, 70, 75-78.
- Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
- Mitchell V, et al, A comparison of midazolam with trimeprazine as an oral premedicant for children., Anaesthesia, 1997, 52, 416-21
- Patel D, et al, Oral midazolam compared with diazepam-droperidol and trimeprazine as premedicants in children., Paediatr Anaesth, 1997, 7:, 287-93
- Sponheim S, et al., Pharmacokinetics of trimeprazine in children, Pharmacol Toxicol, 1990, 67, 243-5
- van der Walt JH, et al, The perioperative effects of oral premedication in children, Anaesth Intensive Care, 1990, 18, 5-10
- Expert opinie Landelijk Werkgroep Wiegendood, Correspondentie met NKFK dd 29 feb 2008
- Sanofi-Aventis Netherlands B.V, SmPC Nedeltran (RVG 01751) 4 oktober 2011, www.cbg-meb.nl
- Evolan Pharma AB, SmPC Alimemazin Evolan (18-12189) 10.05.2021 (Norwegian SMPC), https://www.legemiddelsok.no/
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
